Currently developing a portfolio of products and solutions with UK/EU and Middle East in ZeroCarbon, ZeroWaste renewables, water, waste, energy recycle and conversionStrong interest in new technology development and commercialisation in environment, energy, water, health, public health, rapid diagnostics and sustainable conversion/development of decarbonisation recycling. 40 years experience of market, product and process research & development, commercialisation, sales, management and consultancy.Technology and company transactions include partnering, acquisition, licensing, fundraising and investment with start-ups, SME growth and global corporations. Employment includes ZeroCarbon Ventures, AST Advanced Scientific and Management Consulting, BluewaterBio, ImprintPharma, AEA Technology, Millipore, Portals/(Thames) Water. Clients include both SMEs and international water, energy, renewables, pharmaceutical, medical, health and water companies.Market and Technology Success Areas: * ZeroCarbon ZeroWaste sustainable intelligent recycling, conversion and re-use of energy, fuel and waste * Technology and Market investigation, analysis, strategic planning, partnering, licensing, negotiation, acquisition, deployment, pilot demonstration and commercial scale-up* Medical and consumer product development, manufacture, patents and licensing* Membrane and Separations Technology for water, pharmaceuticals and biotech manufacture* Wastewater recycle using biological and membrane processes, filtration, disinfection, oxidationHighlights include: > Emergency Covid19 risk mitigation plan and technology acquisition of Rapid Diagnostics, HEPA Aerosol Filtration, personnel risk management, communications > investor strategy planning, search and successful acquisition of market leading water technology> developed membrane processes for ultrapure and ultra high-yield drug and biotech product manufacturing, including $bn antibiotics and recombinant hormones, antibodies and enzymes> developed pain-free needle and injector technologies for a number of clients including manufacture, FDA authorisation, CE Mark, ISO 13845, patent, design registration > developed strategic enhancement of ultra-high (500mg/ml) concentration for troubled injectable therapeutic antibody product enabling major transaction> won 5 awards for inventions, sales and new business development> currently developing > have researched and developed and assisted in fundraising for a number of healthcare, diagnostic, water, safety and public health products